menu
back

Press releases

Jeantet advises the group of medical biology laboratories, Biogroup-LCD on the acquisition of Dyomedea-Neolab

Loraine Donnedieu de Vabres-Tranié , Florent Vever

Paris, August 12th, 2020 – Jeantet advised the group of medical biology laboratories, Biogroup-LCD, for the authorization, subject to commitment conditions, by the French Competition Authority of its acquisition of Dyomedea-Neolab, which operates laboratories in the region of Auvergne-Rhône-Alpes.

This operation involving a total of 43 medical biology sites, mainly in the Rhone region of France, with a turnover of approximately €55 million, enables Biogroup-LCD to now operate 710 sites across France, thus affirming its external growth objective.

Resulting from the merger of Biogroup and LCD laboratories in 2015, headed by Stéphane Eimer, Biogroup-LCD is currently the second largest medical biology group in France and the first independent group, with a turnover of €930 million.

Jeantet’s team advising Biogroup-LCD for competition matters included Loraine Donnedieu de Vabres-Tranié, Partner and Florent Vever, Counsel.

Biogroup was also advised by the investment bank Degroof Petercam, the Law Firms Segif and CMS Francis Lefebvre Avocats.

The Dyomedea-Neolab Laboratory was counseled by Akilys Avocats.